Rhabdomyolysis-induced acute kidney injury after administration of red yeast rice supplement: A case report

Wang YH et al. A case of rhabdomyolysis-induced AKI

Ya-Han Wang, Si-Shuo Zhang, Hai-Tao Li, Hong-Wei Zhi, Hong-Yun Wu

Abstract

BACKGROUND
A few reports have revealed induction of rhabdomyolysis by a red yeast rice (RYR) supplement or by RYR in combination with abiraterone (an androgen biosynthesis inhibitor).

CASE SUMMARY
We observed a patient with metastatic castration-resistant prostate cancer taking abiraterone and RYR, with progressive limb weakness, muscle soreness, and acute kidney injury (AKI) within 1 mo, who was diagnosed with rhabdomyolysis-induced AKI. The patient discontinued these drugs and responded well to hemodialysis and hemoperfusion. After 23 d of treatment, creatine kinase levels returned to normal and serum creatinine levels decreased.

CONCLUSION
We speculate that statins, the main lipid-lowering component of RYR, or a combination of statins and abiraterone, will increase the risk of rhabdomyolysis.
**Key Words:** Rhabdomyolysis; Acute kidney injury; Lovastatin; Abiraterone; Case report

Wang YH, Zhang SS, Li HT, Zhi HW, Wu HY. Rhabdomyolysis-induced acute kidney injury after administration of red yeast rice supplement: A case report. *World J Clin Cases* 2023; In press

**Core Tip:** In September 2021, a 76-year-old male presented with muscle soreness, limb weakness, and impaired kidney function. He had been taking the anti-prostate cancer drug abiraterone for 14 mo and had added red yeast rice (RYR) supplements 3 mo before symptom onset. The patient was asked to stop taking these two drugs. He then underwent hemodialysis and hemoperfusion therapy. We measured renal function and muscle damage indicators continuously for 23 d until they returned to normal. The statin content of RYR supplements should be kept in mind, as well as the increased risk of muscle and kidney damage when combined with abiraterone.

**INTRODUCTION**

Abiraterone is an oral 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor that blocks the production of the testosterone precursor dehydroepiandrosterone (DHEA). It was approved by the FDA in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Red yeast rice (RYR) is a dietary supplement for patients with dyslipidemia and is widely consumed by the elderly in most countries[^1]. Its main lipid-lowering component, monacolin K (lovastatin), is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. Lipid-lowering statins, which reduce lipid content in the blood but may impair liver and kidney function or induce muscle damage in combination with abiraterone, can improve the overall survival of patients with mCRPC[^2]. The combined lipid reduction and increased survival in mCRPC is achieved by lowering cholesterol (a DHEA precursor), reducing DHEA transport across cell membranes, and reducing steroid biosynthesis[^3]. However, because cytochrome P450 (CYP) is involved in drug metabolism, oral administration of anticancer drugs
increases the likelihood of drug-drug interactions. Unlike ketoconazole, an earlier treatment in patients with mCSPC, abiraterone has not been reported to interfere with statin metabolism. However, the present case report suggests that the RYR or the RYR-abiraterone interaction may cause rhabdomyolysis.

**CASE PRESENTATION**

**Chief complaints**
A 76-year-old male was admitted to the Neurology Department of our hospital on September 9, 2021, because of weakness and pain below the waist for 1 mo and weakness in both arms for one week.

**History of present illness**
A 76-year-old male was admitted to the Neurology Department of our hospital on September 9, 2021, because of weakness and pain below the waist for 1 mo and weakness in both arms for one week.

**History of past illness**
The patient had been diagnosed with type 2 diabetes mellitus, deep venous thrombosis, and coronary heart disease for over 20 years. He took metformin and betaloc regularly and was injected with aspartic insulin and insulin glycine. The patient had been diagnosed with mCRPC 14 mo previously and treated with abiraterone (1 g/d po QD). Three months earlier, the patient began to take 1.2 g/d of an oral supplement, RYR/ginseng/ginkgo leaf capsule (Shanghai Komen Technology Medicine Co., Ltd.; active ingredient 2 000 mg lovastatin per 100 g), thus ingesting ca. 24 mg/d of lovastatin. The patient's medical history is shown in Figure 1.

**Personal and family history**
Based on a questionnaire survey, no other family members experienced similar symptoms.
Physical examination

Limb muscle tenderness (+), proximal and distal muscle strength of the arms (IV), proximal muscle strength of the lower limbs (II), distal muscle strength of the lower limbs (III), bilateral muscle reflex (++), and bilateral tendon reflex (+).

Laboratory examinations

Blood chemical examination (2021/9/16): Mild anemia (red blood cell 3.39 × 10^{12} L^{-1}, hemoglobin 106 g/L), mild hyponatremia (Na+ 135 mmol/L), elevated erythrocyte sedimentation rate 62 mm/h, C-reaction protein (CRP) 105 mg/L, complement C3 (C3) 1.57 g/L, reduced immunoglobulin G 7.71 g/L and immunoglobulin M < 0.181 g/L, elevated transaminase (alanine aminotransferase 643 U/L, aspartate aminotransferase 176 U/L, kidney injury, and elevated myocardial enzymes: Serum creatinine (Scr) 315 µmol/L, lactate dehydrogenase (LDH) 1182 U/L, and creatine kinase (CK) 18230 U/L. The cerebrospinal fluid test was normal.

Imaging examinations

Three-dimensional computed tomography imaging showed degenerative changes in the lumbar spine as well as L2/3 and L3/4 disk bulge. Electromyography showed neurogenic damage of the upper and lower extremities (peripheral nerve damage of the upper and lower extremities involving sensory and motor fibers as well as L5 and S1 Levels). There was no muscle atrophy or tremor; no skin rash on the eyelids, extensor limbs, or v-zone of the fore-chest or shoulder area of the back; and no joint swelling or pain. Magnetic resonance examination revealed diffuse abnormal signals in the erector spinae, with lumbar disc herniation (Figure 2).

FINAL DIAGNOSIS

Considering the patient’s symptoms, magnetic resonance imaging findings, and progressively increasing CK and Scr levels, rhabdomyolysis-induced acute kidney
injury (AKI) was diagnosed. Unfortunately, the patient refused muscle biopsy, so histopathological evidence was not obtained.

TREATMENT

Abiraterone and supplements were discontinued after admission, and other drugs continued to be administered. The patient responded well to hemodialysis, hemoperfusion, ATP disodium injections (40 mg iv drip QD), levocarnitine injection (2 g iv drip QD), Ringer’s fluid (250 mL iv drip QD), sodium bicarbonate tablets (1 g po TID), vitamin B2 (30 mg po TID), and coenzyme Q10 (10 mg po TID). On day 6 of treatment (2021/9/22), CK levels were significantly reduced. The patient was hospitalized for 23 d. Upon discharge (2021/10/8), CK levels were normal (93 U/L), LDH levels were close to normal (290 U/L), and Scr levels (281 μmol/L) required continued monitoring. Changes in the patient’s key laboratory indicators are shown in Figure 3.

OUTCOME AND FOLLOW-UP

During hospitalization, no adverse events were observed. The patient received hemodialysis and hemoperfusion every day, tolerated intravenous infusion and oral drug administration well, and was satisfied with the treatment effect. After discharge, the patient resumed all previous medications except for RYR supplement. Based on telephonic follow-up, Scr decreased to 190 μmol/L almost 1 mo after discharge, and rhabdomyolysis did not recur. The patient reported no further complaints.

DISCUSSION

We report a case of AKI caused by drug-induced rhabdomyolysis. Muscle pain and weakness occurred 2 mo after administration of the combination of RYR/ginseng/ginkgo leaf capsules (key ingredient: lovastatin) and abiraterone. Although there have been a few reports of abiraterone-induced rhabdomyolysis[4], the patient did not develop symptoms during the first 11 mo of abiraterone treatment and did not undergo dose adjustment. However, the patient showed progressively
aggravated myasthenia and myalgia 2 mo after RYR/ginseng/ginkgo leaf compound supplementation. This supplement contained lovastatin, and the daily oral dose exceeded the recommended dose of 20 mg/day. The patient continued taking an immunosuppressant. **No other identifiable specific triggers for rhabdomyolysis** (such as decompensated hypothyroidism, liver disease, strenuous exercise, or recreational drugs) **were** found in the patient’s medical history or physical examination. In addition, abiraterone therapy was well-tolerated after discharge. Therefore, we believe that the AKI caused by rhabdomyolysis in this patient was caused by an overdose of lovastatin or a drug-drug interaction between lovastatin and abiraterone.

Abiraterone is an androgen biosynthesis inhibitor that inhibits DHEA, testosterone, and dihydrotestosterone production by inhibiting the activity of the metabolic enzyme CYP17A1. Therefore, it is suitable for the treatment of mCRPC. Abiraterone has side-effects associated with CYP17A1 inhibition, namely, reduced cortisol secretion, increased adrenocorticoid release, increased corticoid secretion, and hypokalemia, all of which are risk factors for rhabdomyolysis[5]. In a large, real-world cohort study, Japanese researchers tracked the safety and efficacy of abiraterone in combination with prednisone in 492 patients with mCRPC who were followed up for 24 mo. No new or unpredictable adverse events were observed in a market-release study of abiraterone[6]. The frequent adverse events observed at follow-up were similar to those observed in market-release clinical studies, including hypokalemia (3.0%) and abnormal liver function (6.5%)[6]. Hepatotoxicity was the most common adverse drug reaction. Most patients recovered after abiraterone treatment were discontinued[6]. In our case, however, the patient did not have hypokalemia upon admission, and did not show symptoms of myopathy during the first 11 mo of abiraterone treatment; therefore, we speculate that rhabdomyolysis and acute kidney injury were not caused by abiraterone alone.

Although our patient had no clear history of hyperlipidemia, he had been administered lovastatin 3 mo before hospitalization. To date, there have been no reports on rhabdomyolysis or acute kidney injury caused by ginseng or ginkgo biloba.
Although RYR is a traditional medicinal material that can be used in both medicine and food, and its potential for lowering blood lipids has been demonstrated in numerous studies\(^7\), lovastatin is the main active ingredient among its many chemical components. According to the package insert, lovastatin is present at 2 000 mg / 100 g RYR. Our patient ingested a 1.2 g capsule per day, equivalent to 24 mg of lovastatin.

Statins prevent cardiovascular diseases by inhibiting HMG-CoA reductase, thus inhibiting cholesterol synthesis, and thereby reducing serum cholesterol levels\(^2\). There is increasing evidence that statins also play a role in the treatment of cancers, including colon, breast, and prostate cancers\(^5,7,8\). Laboratory studies have shown that statins can limit cancer progression by promoting apoptosis and inflammatory responses and by inhibiting cancer cell proliferation, adhesion, and angiogenesis\(^9-12\). A meta-analysis reported that patients with mCRPC may benefit from treatment with abiraterone or enzalutamide in combination with statins\(^13\). In addition to lowering cholesterol, statins compete to inhibit DHEA uptake by binding to solute carrier transporters (SLCO2B1), thereby effectively reducing the pool of androgens available in tumors. This may explain why statins reduce the incidence of prostate cancer and improve prognosis\(^9,10\).

Furthermore, abiraterone and lovastatin do not exhibit adverse drug-drug interactions in the vast majority of mCRPC patients, and their combined use increases survival and cancer-related mortality in patients with mCRPC\(^9\). However, in addition to inhibiting cholesterol synthesis, statins can also lead to coenzyme Q10 deficiency, resulting in mitochondrial dysfunction, and thereby inhibiting energy production, reducing cell energy levels, reducing intermediate metabolite synthesis during cholesterol synthesis, affecting the synthesis of important proteins, and reducing the supply of cholesterol to cell membranes\(^2\). The consequent increase in membrane permeability and instability leads to increased intracellular calcium concentration and cell death. These mechanisms increase the risk of statin-induced rhabdomyolysis\(^8\).

Prior to the development of abiraterone and its approval as an adrenal androgen synthesis inhibitor, patients were treated with ketoconazole, a CYP3A4 inhibitor that causes elevated plasma concentrations of statins and increases the risk of
rhabdomyolysis\cite{12}. In contrast, abiraterone acts only on CYP17A1 without significantly affecting statin metabolism. However, in vitro studies have shown that abiraterone metabolites inhibit organic anion transport polypeptide 1B1 (OATP1B1). Theoretically, this transporter affects the uptake of multiple exogenous drugs, including lovastatin. OATP1B1 inhibition increases lovastatin levels, resulting in increased drug toxicity\cite{13,14}. Statin-induced rhabdomyolysis is dose-dependent, especially when statins are used in conjunction with a muscle-toxic agent or drug that can increase their concentration. However, several reports have suggested that interactions between lovastatin and abiraterone cause rhabdomyolysis and AKI\cite{15}.

**CONCLUSION**

RYR supplements have been found to reduce low-density lipoprotein cholesterol levels as effectively as medium-dose statins, and they are a good treatment option for patients who are intolerant to statins. However, the daily dose of lovastatin in RYR supplements and the appropriate dose in combination with abiraterone for patients with mCSPC should be carefully considered. This case highlights the possibility of kidney injury resulting from rhabdomyolysis caused by this drug combination. More attention should be paid to drug-drug interactions in clinical treatment.

**ACKNOWLEDGEMENTS**

We would like to thank Professor Wen-Qiang Cui for his guidance in writing this paper.
| 主要来源 | 详细信息 |
|---------|----------|
| 1. | Neyra, Javier A., Natalia A. Rocha, Rhea Bhargava, Omkar U. Vaidya, Allen R. Hendricks, and Aylin R. Rodan. "Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report", BMC Nephrology, 2015. Crossref |
| 2. | patents.justia.com |
| 3. | doaj.org |
| 4. | www.semanticscholar.org |